Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).

Lung cancer (Amsterdam, Netherlands) - 1 Feb 2017

Tiseo Marcello, Damato Angela, Longo Lucia, Barbieri Fausto, Bertolini Federica, Stefani Alessandro, Migaldi Mario, Gnetti Letizia, Camisa Roberta, Bordi Paola, Buti Sebastiano, Rossi Giulio

Abstract excerpt

INTRODUCTION: Thymic epithelial tumors (TETs) are rare neoplasms with different prognosis lacking consistent molecular alterations possibly leading to targeted therapy. We collected a consecutive series of TETs aimed at investigating the mutational status of druggable genes (EGFR, c-KIT, KRAS, BRAF, PDGFR-alpha and -beta, HER2 and c-MET) and the expression of ALK and PD-L1. PATIENTS AND METHODS: One hundred...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms, Glandular and Epithelial

Share to Proto-Oncogene Proteins c-kit

Share to Receptor Protein-Tyrosine Kinases

Share to Thymoma

Share to Thymus Gland

Share to Thymus Neoplasms

Source

Identifiers

PMID: 28212996
DOI: 10.1016/j.lungcan.2016.12.005

Genes

ALK
KIT
BRAF
EGFR
KRAS
MET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).PMID 28212996Read ↗

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial TumorsSemantic proximity Read ↗

Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets.Semantic proximity Read ↗

Medical treatment involving investigational drugs and genetic profile of thymic carcinoma.Semantic proximity Read ↗

Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers.Semantic proximity Read ↗

Thymic epithelial tumors: From biology to treatment.Semantic proximity Read ↗

Molecular landscape of thymic epithelial tumors.Semantic proximity Read ↗

Integrated Molecular and Clinical Analysis of Thymic Epithelial Tumors.Semantic proximity Read ↗

The Molecular Landscape of Thymic Epithelial Tumors: A Comprehensive ReviewSemantic proximity Read ↗

Thymic epithelial tumours: from basic principles to individualised treatment strategies.Semantic proximity Read ↗

Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in KIT, ERBB2, KRAS, and TP53 in 30% of Thymic CarcinomasSemantic proximity Read ↗

Genomic characterization of thymic epithelial tumors in a real-world datasetSemantic proximity Read ↗

Mutation Profile of Thymic Carcinoma and Thymic Neuroendocrine Tumor by Targeted Next-generation Sequencing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.